CLINICAL_TRIALS
trial_result
· 2016-01-28
Clinical Trial Update: Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses [Phase 2]
Summary
Phase 2 trial evaluated the safety of PEP005 topical gel at 0.025% and 0.05% in patients with actinic keratosis; the study has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Peplin | Conditions: Actinic Keratosis | Phase 2 | Status: COMPLETED